Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Current Deferred Revenue (2018 - 2026)

Anika Therapeutics has reported Current Deferred Revenue over the past 8 years, most recently at $229000.0 for Q1 2026.

Quarterly Current Deferred Revenue changed N/A to $229000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $229000.0 through Mar 2026, changed N/A year-over-year, with the annual reading at $24510.0 for FY2014, 98.9% down from the prior year.
Current Deferred Revenue was $229000.0 for Q1 2026 at Anika Therapeutics, up from $52000.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $229000.0 in Q1 2026 and troughed at $229000.0 in Q1 2026.